Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 471

1.

Antibiotics in the clinical pipeline in October 2019.

Butler MS, Paterson DL.

J Antibiot (Tokyo). 2020 Mar 10. doi: 10.1038/s41429-020-0291-8. [Epub ahead of print] Review.

PMID:
32152527
2.

Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study.

van Duin D, Arias CA, Komarow L, Chen L, Hanson BM, Weston G, Cober E, Garner OB, Jacob JT, Satlin MJ, Fries BC, Garcia-Diaz J, Doi Y, Dhar S, Kaye KS, Earley M, Hujer AM, Hujer KM, Domitrovic TN, Shropshire WC, Dinh A, Manca C, Luterbach CL, Wang M, Paterson DL, Banerjee R, Patel R, Evans S, Hill C, Arias R, Chambers HF, Fowler VG Jr, Kreiswirth BN, Bonomo RA; Multi-Drug Resistant Organism Network Investigators.

Lancet Infect Dis. 2020 Mar 6. pii: S1473-3099(19)30755-8. doi: 10.1016/S1473-3099(19)30755-8. [Epub ahead of print]

PMID:
32151332
3.

Genomic investigation reveals contaminated detergent as the source of an ESBL-producing Klebsiella michiganensis outbreak in a neonatal unit.

Chapman P, Forde BM, Roberts LW, Bergh H, Vesey D, Jennison AV, Moss S, Paterson DL, Beatson SA, Harris PNA.

J Clin Microbiol. 2020 Feb 26. pii: JCM.01980-19. doi: 10.1128/JCM.01980-19. [Epub ahead of print]

PMID:
32102855
4.

New treatment options for multiresistant gram negatives.

Paterson DL, Isler B, Stewart A.

Curr Opin Infect Dis. 2020 Apr;33(2):214-223. doi: 10.1097/QCO.0000000000000627.

PMID:
32068644
5.

Fracture-related infection: current methods for prevention and treatment.

Foster AL, Moriarty TF, Trampuz A, Jaiprakash A, Burch MA, Crawford R, Paterson DL, Metsemakers WJ, Schuetz M, Richards RG.

Expert Rev Anti Infect Ther. 2020 Apr;18(4):307-321. doi: 10.1080/14787210.2020.1729740. Epub 2020 Feb 19.

PMID:
32049563
6.

Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.

Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, Archuleta S, Roberts MA, Cass A, Paterson DL, Foo H, Paul M, Guy SD, Tramontana AR, Walls GB, McBride S, Bak N, Ghosh N, Rogers BA, Ralph AP, Davies J, Ferguson PE, Dotel R, McKew GL, Gray TJ, Holmes NE, Smith S, Warner MS, Kalimuddin S, Young BE, Runnegar N, Andresen DN, Anagnostou NA, Johnson SA, Chatfield MD, Cheng AC, Fowler VG Jr, Howden BP, Meagher N, Price DJ, van Hal SJ, O'Sullivan MVN, Davis JS; Australasian Society for Infectious Diseases Clinical Research Network.

JAMA. 2020 Feb 11;323(6):527-537. doi: 10.1001/jama.2020.0103.

PMID:
32044943
7.

Evaluation of quick sequential organ failure assessment and systemic inflammatory response syndrome in patients with gram negative bloodstream infection.

McNamara JF, Avent M, Stewart A, Kwan C, Paterson DL.

Infect Dis Health. 2020 Jan 28. pii: S2468-0451(20)30003-1. doi: 10.1016/j.idh.2020.01.003. [Epub ahead of print]

PMID:
32005586
8.

Integrating multiple genomic technologies to investigate an outbreak of carbapenemase-producing Enterobacter hormaechei.

Roberts LW, Harris PNA, Forde BM, Ben Zakour NL, Catchpoole E, Stanton-Cook M, Phan MD, Sidjabat HE, Bergh H, Heney C, Gawthorne JA, Lipman J, Allworth A, Chan KG, Chong TM, Yin WF, Schembri MA, Paterson DL, Beatson SA.

Nat Commun. 2020 Jan 24;11(1):466. doi: 10.1038/s41467-019-14139-5.

9.

Genomic analysis of carbapenemase-producing Enterobacteriaceae in Queensland reveals widespread transmission of bla IMP-4 on an IncHI2 plasmid.

Roberts LW, Catchpoole E, Jennison AV, Bergh H, Hume A, Heney C, George N, Paterson DL, Schembri MA, Beatson SA, Harris PNA.

Microb Genom. 2020 Jan;6(1). doi: 10.1099/mgen.0.000321. Epub 2019 Dec 19.

10.

Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia.

Paterson DL, Henderson A, Harris PNA.

Curr Opin Infect Dis. 2020 Feb;33(1):78-85. doi: 10.1097/QCO.0000000000000623.

PMID:
31834029
11.

Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study.

Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Fattah MA, Haquin J, MacGowan A, Grier S, Chazan B, Yanovskay A, Ami RB, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, Buhl M, Maurer S, Rodriguez-Bano J, Morales I, Oliver A, de Gopegui ER, Cano A, Machuca I, Gozalo-Marguello M, Martinez-Martinez L, Gonzalez-Barbera EM, Alfaro IG, Salavert M, Beovic B, Saje A, Mueller-Premru M, Pagani L, Vitrat V, Kofteridis D, Zacharioudaki M, Maraki S, Weissman Y, Paul M, Dickstein Y, Leibovici L, Yahav D.

Int J Antimicrob Agents. 2020 Feb;55(2):105847. doi: 10.1016/j.ijantimicag.2019.11.004. Epub 2019 Nov 23.

PMID:
31770625
12.

Modern clinician-initiated clinical trials to determine optimal therapy for multi-drug resistant Gram-negative infections.

Stewart AG, Harris PNA, Chatfield M, Evans SR, van Duin D, Paterson DL.

Clin Infect Dis. 2019 Nov 18. pii: ciz1132. doi: 10.1093/cid/ciz1132. [Epub ahead of print]

PMID:
31738398
13.

Measuring patient-centred long-term outcome following a bloodstream infection: a pilot study.

McNamara JF, Harris PNA, Chatfield MD, Lorenc P, Paterson DL.

Clin Microbiol Infect. 2020 Feb;26(2):257.e1-257.e4. doi: 10.1016/j.cmi.2019.10.011. Epub 2019 Oct 23.

PMID:
31654791
14.

Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.

Yadav R, Bergen PJ, Rogers KE, Kirkpatrick CMJ, Wallis SC, Huang Y, Bulitta JB, Paterson DL, Lipman J, Nation RL, Roberts JA, Landersdorfer CB.

Antimicrob Agents Chemother. 2019 Dec 20;64(1). pii: e01679-19. doi: 10.1128/AAC.01679-19. Print 2019 Dec 20.

PMID:
31636062
15.

Diagnosis of urinary tract infection in older persons in the emergency department: To pee or not to pee, that is the question.

Burkett E, Carpenter CR, Arendts G, Hullick C, Paterson DL, Caterino JM.

Emerg Med Australas. 2019 Oct;31(5):856-862. doi: 10.1111/1742-6723.13376. Epub 2019 Sep 2. No abstract available.

PMID:
31478344
16.

Bacterial identification using a SCIEX 5800 TOF/TOF MALDI research instrument and an external database.

Huber CA, Pflüger V, Reed S, Cottrell K, Sidjabat HE, Ranasinghe A, Zowawi HM, Harris P, Paterson DL.

J Microbiol Methods. 2019 Sep;164:105685. doi: 10.1016/j.mimet.2019.105685. Epub 2019 Aug 7.

PMID:
31400360
17.

Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.

Marimuthu K, Ng OT, Cherng BPZ, Fong RKC, Pada SK, De PP, Ooi ST, Smitasin N, Thoon KC, Krishnan PU, Ang MLT, Chan DSG, Kwa ALH, Deepak RN, Chan YK, Chan YFZ, Huan X, Zaw Linn K, Tee NWS, Tan TY, Koh TH, Lin RTP, Hsu LY, Sengupta S, Paterson DL, Perencevich E, Harbarth S, Teo J, Venkatachalam I; CaPES Study Group.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00845-19. doi: 10.1128/AAC.00845-19. Print 2019 Oct.

18.

Multidrug-Resistant Gram-Negative Pathogens: The Urgent Need for 'Old' Polymyxins.

Paterson DL, Bonomo RA.

Adv Exp Med Biol. 2019;1145:9-13. doi: 10.1007/978-3-030-16373-0_2. Review.

PMID:
31364068
19.

Cost-effectiveness of an environmental cleaning bundle for reducing healthcare associated infections.

White NM, Barnett AG, Hall L, Mitchell BG, Farrington A, Halton K, Paterson DL, Riley TV, Gardner A, Page K, Gericke CA, Graves N.

Clin Infect Dis. 2019 Jul 30. pii: ciz717. doi: 10.1093/cid/ciz717. [Epub ahead of print]

PMID:
31359053
20.

Skin colonization at peripheral intravenous catheter insertion sites increases the risk of catheter colonization and infection.

Choudhury MA, Sidjabat HE, Zowawi HM, Marsh PhD N, Larsen E, Runnegar PhD N, Paterson DL, McMillan DJ, Rickard CM.

Am J Infect Control. 2019 Dec;47(12):1484-1488. doi: 10.1016/j.ajic.2019.06.002. Epub 2019 Jul 19.

PMID:
31331714
21.

Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection - a multi-site retrospective study.

Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Abdel Fattah M, Haquin J, Macgowan A, Grier S, Gibbs J, Chazan B, Yanovskay A, Ben Ami R, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, Buhl M, Mauer S, Bano JR, Morales I, Oliver A, Ruiz de Gopegui E, Cano A, Machuca I, Gozalo-Marguello M, Martinez LM, Gonzalez-Barbera EM, Alfaro IG, Salavert M, Beovic B, Saje A, Mueller-Premru M, Pagani L, Vitrat V, Kofteridis D, Zacharioudaki M, Maraki S, Weissman Y, Paul M, Dickstein Y, Leibovici L, Yahav D.

Clin Infect Dis. 2019 Jul 17. pii: ciz668. doi: 10.1093/cid/ciz668. [Epub ahead of print]

PMID:
31323088
22.

Evaluation of the SpeeDx Carba (beta) multiplex real-time PCR assay for detection of NDM, KPC, OXA-48-like, IMP-4-like and VIM carbapenemase genes.

Bordin A, Trembizki E, Windsor M, Wee R, Tan LY, Buckley C, Syrmis M, Bergh H, Cottrell K, Zowawi HM, Sidjabat HE, Harris PNA, Nimmo GR, Paterson DL, Whiley DM.

BMC Infect Dis. 2019 Jul 2;19(1):571. doi: 10.1186/s12879-019-4176-z.

23.

The risk of resistance: what are the major antimicrobial resistance threats facing Australia?

Williamson DA, Howden BP, Paterson DL.

Med J Aust. 2019 Aug;211(3):103-105.e1. doi: 10.5694/mja2.50249. Epub 2019 Jun 23. No abstract available.

PMID:
31231807
24.

Health Risks of Flood Disasters.

Paterson DL, Wright H, Harris PNA.

Clin Infect Dis. 2018 Oct 15;67(9):1450-1454. doi: 10.1093/cid/ciy227. Review.

PMID:
30986298
25.

Antimicrobial treatment challenges in the era of carbapenem resistance.

Peri AM, Doi Y, Potoski BA, Harris PNA, Paterson DL, Righi E.

Diagn Microbiol Infect Dis. 2019 Aug;94(4):413-425. doi: 10.1016/j.diagmicrobio.2019.01.020. Epub 2019 Feb 5. Review.

PMID:
30905487
26.

An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial.

Mitchell BG, Hall L, White N, Barnett AG, Halton K, Paterson DL, Riley TV, Gardner A, Page K, Farrington A, Gericke CA, Graves N.

Lancet Infect Dis. 2019 Apr;19(4):410-418. doi: 10.1016/S1473-3099(18)30714-X. Epub 2019 Mar 8.

PMID:
30858014
27.

A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.

Lipman J, Brett SJ, De Waele JJ, Cotta MO, Davis JS, Finfer S, Glass P, Knowles S, McGuinness S, Myburgh J, Paterson DL, Peake S, Rajbhandari D, Rhodes A, Roberts JA, Shirwadkar C, Starr T, Taylor C, Billot L, Dulhunty JM.

Crit Care Resusc. 2019 Mar;21(1):63-68.

PMID:
30857514
28.

Incidence of community onset MRSA in Australia: least reported where it is Most prevalent.

Cameron JK, Hall L, Tong SYC, Paterson DL, Halton K.

Antimicrob Resist Infect Control. 2019 Feb 12;8:33. doi: 10.1186/s13756-019-0485-7. eCollection 2019.

29.

Antibiotics for Ceftriaxone Resistant Gram-Negative Bacterial Bloodstream Infections-Reply.

Harris PNA, Tambyah P, Paterson DL.

JAMA. 2019 Feb 12;321(6):613. doi: 10.1001/jama.2018.19353. No abstract available.

PMID:
30747963
30.

Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae.

Lin YW, Abdul Rahim N, Zhao J, Han ML, Yu HH, Wickremasinghe H, Chen K, Wang J, Paterson DL, Zhu Y, Rao GG, Zhou QT, Forrest A, Velkov T, Li J.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02176-18. doi: 10.1128/AAC.02176-18. Print 2019 Apr.

31.

Fosfomycin: what was old is new again.

Avent ML, Rogers BA, Cheng AC, Athan E, Francis JR, Roberts MJ, Paterson DL, Harris PNA.

Intern Med J. 2018 Dec;48(12):1425-1429. doi: 10.1111/imj.14122. No abstract available.

PMID:
30517987
32.

Transmission of mcr-1-Producing Multidrug-resistant Enterobacteriaceae in Public Transportation in Guangzhou, China.

Shen C, Feng S, Chen H, Dai M, Paterson DL, Zheng X, Wu X, Zhong LL, Liu Y, Xia Y, Ma R, Huang X, Tian GB.

Clin Infect Dis. 2018 Nov 13;67(suppl_2):S217-S224. doi: 10.1093/cid/ciy661.

PMID:
30423047
33.

Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.

Henderson A, Tan E, McCarthy KL, Paterson DL.

Pathology. 2018 Dec;50(7):748-752. doi: 10.1016/j.pathol.2018.08.009. Epub 2018 Nov 2.

PMID:
30392710
34.

Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS).

Evans SR, Follmann D, Liu Y, Holland T, Doernberg SB, Rouphael N, Hamasaki T, Jiang Y, Lok JJ, Tran TTT, Harris AD, Fowler VG, Boucher H, Kreiswirth BN, Bonomo RA, Van Duin D, Paterson DL, Chambers H.

Clin Infect Dis. 2019 May 17;68(11):1961-1967. doi: 10.1093/cid/ciy912.

35.

New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections.

Isler B, Doi Y, Bonomo RA, Paterson DL.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01110-18. doi: 10.1128/AAC.01110-18. Print 2019 Jan. Review.

36.

Discovery of mcr-1-Mediated Colistin Resistance in a Highly Virulent Escherichia coli Lineage.

Forde BM, Zowawi HM, Harris PNA, Roberts L, Ibrahim E, Shaikh N, Deshmukh A, Sid Ahmed MA, Al Maslamani M, Cottrell K, Trembizki E, Sundac L, Yu HH, Li J, Schembri MA, Whiley DM, Paterson DL, Beatson SA.

mSphere. 2018 Oct 10;3(5). pii: e00486-18. doi: 10.1128/mSphere.00486-18.

37.

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.

Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN).

JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163. Erratum in: JAMA. 2019 Jun 18;321(23):2370.

38.

Spread of MCR-3 Colistin Resistance in China: An Epidemiological, Genomic and Mechanistic Study.

Xu Y, Zhong LL, Srinivas S, Sun J, Huang M, Paterson DL, Lei S, Lin J, Li X, Tang Z, Feng S, Shen C, Tian GB, Feng Y.

EBioMedicine. 2018 Aug;34:139-157. doi: 10.1016/j.ebiom.2018.07.027. Epub 2018 Jul 27.

39.

Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.

Russo A, Falcone M, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Cisneros JM, Hernández-Torres A, Farcomeni A, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Karaiskos I, de la Calle C, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Mora-Rillo M, Rodriguez-Gomez J, Souli M, Bonomo RA, Paterson DL, Carmeli Y, Pascual A, Rodríguez-Baño J, Venditti M; REIPI/ESGBIS/INCREMENT investigators.

Int J Antimicrob Agents. 2018 Nov;52(5):577-585. doi: 10.1016/j.ijantimicag.2018.06.018. Epub 2018 Jun 30.

PMID:
29969692
40.

Long-term morbidity and mortality following bloodstream infection: A systematic literature review.

McNamara JF, Righi E, Wright H, Hartel GF, Harris PNA, Paterson DL.

J Infect. 2018 Jul;77(1):1-8. doi: 10.1016/j.jinf.2018.03.005. Epub 2018 May 7.

PMID:
29746948
41.

Identification of carbapenem-resistant Pseudomonas aeruginosa in selected hospitals of the Gulf Cooperation Council States: dominance of high-risk clones in the region.

Zowawi HM, Syrmis MW, Kidd TJ, Balkhy HH, Walsh TR, Al Johani SM, Al Jindan RY, Alfaresi M, Ibrahim E, Al-Jardani A, Al Salman J, Dashti AA, Sidjabat HE, Baz O, Trembizki E, Whiley DM, Paterson DL.

J Med Microbiol. 2018 Jun;67(6):846-853. doi: 10.1099/jmm.0.000730. Epub 2018 Apr 17.

PMID:
29664716
42.

P. aeruginosa blood stream infection isolates: A "full house" of virulence genes in isolates associated with rapid patient death and patient survival.

McCarthy KL, Wailan AM, Jennison AV, Kidd TJ, Paterson DL.

Microb Pathog. 2018 Jun;119:81-85. doi: 10.1016/j.micpath.2018.03.062. Epub 2018 Apr 3.

PMID:
29621565
43.

Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae.

Scheuerman O, Schechner V, Carmeli Y, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Molina J, Hernández-Torres A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Karaiskos I, de la Calle C, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Navarro-San Francisco C, Bonomo RA, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT investigators.

Infect Control Hosp Epidemiol. 2018 Jun;39(6):660-667. doi: 10.1017/ice.2018.63. Epub 2018 Apr 5.

PMID:
29618394
44.

Changes in knowledge and attitudes of hospital environmental services staff: The Researching Effective Approaches to Cleaning in Hospitals (REACH) study.

Mitchell BG, White N, Farrington A, Allen M, Page K, Gardner A, Halton K, Riley TV, Gericke CA, Paterson DL, Graves N, Hall L.

Am J Infect Control. 2018 Sep;46(9):980-985. doi: 10.1016/j.ajic.2018.02.003. Epub 2018 Mar 14.

45.

Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.

Avery RK, Silveira FP, Benedict K, Cleveland AA, Kauffman CA, Schuster MG, Dubberke ER, Husain S, Paterson DL, Chiller T, Pappas P.

Transpl Infect Dis. 2018 Jun;20(3):e12877. doi: 10.1111/tid.12877. Epub 2018 Mar 30.

46.

The use of SWATH to analyse the dynamic changes of bacterial proteome of carbapanemase-producing Escherichia coli under antibiotic pressure.

Sidjabat HE, Gien J, Kvaskoff D, Ashman K, Vaswani K, Reed S, McGeary RP, Paterson DL, Bordin A, Schenk G.

Sci Rep. 2018 Mar 1;8(1):3871. doi: 10.1038/s41598-018-21984-9.

47.

Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Yadav R, Rogers KE, Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00078-18. doi: 10.1128/AAC.00078-18. Print 2018 May.

48.

Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.

Bergen PJ, Bulitta JB, Sime FB, Lipman J, McGregor MJ, Millen N, Paterson DL, Kirkpatrick CMJ, Roberts JA, Landersdorfer CB.

Diagn Microbiol Infect Dis. 2018 May;91(1):69-76. doi: 10.1016/j.diagmicrobio.2017.12.019. Epub 2018 Jan 3.

PMID:
29395712
49.

Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria.

Blaskovich MAT, Hansford KA, Gong Y, Butler MS, Muldoon C, Huang JX, Ramu S, Silva AB, Cheng M, Kavanagh AM, Ziora Z, Premraj R, Lindahl F, Bradford TA, Lee JC, Karoli T, Pelingon R, Edwards DJ, Amado M, Elliott AG, Phetsang W, Daud NH, Deecke JE, Sidjabat HE, Ramaologa S, Zuegg J, Betley JR, Beevers APG, Smith RAG, Roberts JA, Paterson DL, Cooper MA.

Nat Commun. 2018 Jan 2;9(1):22. doi: 10.1038/s41467-017-02123-w.

50.

Whole genome analysis of cephalosporin-resistant Escherichia coli from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27.

Harris PNA, Ben Zakour NL, Roberts LW, Wailan AM, Zowawi HM, Tambyah PA, Lye DC, Jureen R, Lee TH, Yin M, Izharuddin E, Looke D, Runnegar N, Rogers B, Bhally H, Crowe A, Schembri MA, Beatson SA, Paterson DL; MERINO Trial investigators.

J Antimicrob Chemother. 2018 Mar 1;73(3):634-642. doi: 10.1093/jac/dkx466.

PMID:
29253152

Supplemental Content

Loading ...
Support Center